Paclitaxel anticancer activity is enhanced by the MEK 1/2 inhibitor PD98059 in vitro and by PD98059-loaded nanoparticles in BRAFV600E melanoma-bearing mice
Aml I. Mekkawy, Youssef W. Naguib, Suhaila O. Alhaj‐Suliman, Emad I. Wafa, Kareem Ebeid, Timothy M. Acri, Aliasger K. Salem
Topics & Concepts
CytotoxicityMelanomaPaclitaxelIn vivoIn vitroMAPK/ERK pathwayMEK inhibitorPharmacologyChemistryIC50Cancer researchKinaseMedicineChemotherapyBiologyBiochemistryInternal medicineBiotechnologyMelanoma and MAPK PathwaysCellular Mechanics and InteractionsImmunotherapy and Immune Responses